60 Degrees Pharma's B-FREE Study for Chronic Babesiosis Begins Patient Enrollment.

60 Degrees Pharmaceuticals has announced the opening of the Cohen Center for Recovery from Complex Chronic Diseases at Mount Sinai Icahn School of Medicine as the central study site for the B-FREE Chronic Babesiosis Study. The study will evaluate tafenoquine treatment for chronic babesiosis, a vector-borne disease with an estimated unmet medical need of 4,400 to 190,000 cases annually. The study will run for approximately 12 months and enroll up to 100 patients.